We believe that our results showing frequent BRCA2, EGFR, and NTRK mutations in MSI-H CRC patients, and potentially other cancers with mismatch repair deficiency, offer immediate novel personalized medicine strategies to treat the patients with advanced disease who may have no remaining treatment options. This evidence concerns the gene BRCA2 and colorectal carcinoma.